Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 992

1.

Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.

Clark JI, Kancharla K, Qamar R, Fisher S, Hantel A, Panganiban J, Millbrandt L, Albain KS.

Lung Cancer. 2001 Nov;34(2):271-7.

PMID:
11679186
2.

Combination chemotherapy with docetaxel, vinorelbine and cisplatin as first-line treatment of advanced non-small-cell lung cancer: a multicenter phase II study of the Greek Cooperative Group for Lung Cancer.

Georgoulias V, Androulakis N, Bouros D, Kouroussis C, Chatzakis K, Papadakis M, Apostopoloulou F, Georgopoulou T, Kotsakis T, Souklakos J, Hatzidaki D, Vlachonikolis J, Panagos G.

Lung Cancer. 1998 Sep;21(3):213-20.

PMID:
9857999
3.

Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study.

Pérol M, Léna H, Thomas P, Robinet G, Fournel P, Coste E, Belleguic C, Le Caer H, Blanchon F, Vergnenègre A, Vernejoux JM, Schuller-Lebeau MP, Pham E.

Ann Oncol. 2002 May;13(5):742-7.

PMID:
12075743
4.

First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.

Kourousis C, Androulakis N, Kakolyris S, Souglakos J, Maltezakis G, Metaxaris G, Chalkiadakis G, Samonis G, Vlachonikolis J, Georgoulias V.

Cancer. 1998 Nov 15;83(10):2083-90.

PMID:
9827712
5.

Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.

Edelman MJ, Clark JI, Chansky K, Albain K, Bhoopalam N, Weiss GR, Giguere JK, Kelly K, Crowley J, Gandara DR.

Clin Cancer Res. 2004 Aug 1;10(15):5022-6.

6.
7.
8.

The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.

Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G Jr, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS.

Cancer. 2002 Jul 15;95(2):340-53. Erratum in: Cancer. 2003 Mar 1;97(5):1367.

9.

Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study.

Feliu J, Martin G, Lizón J, Chacón JI, Dorta J, de Castro J, Rodríguez A, Sánchez Heras B, Torrego JC, Espinosa E, González Barón M; Oncopaz Cooperative Group, Spain.

Ann Oncol. 2001 Oct;12(10):1369-74.

PMID:
11762806
10.

Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.

Kwon JH, Kim JH, Lee JA, Shin HC, Kim HJ, Song HH, Jung JY, Kim HY, Choi DR, Kim HS, Park YI, Zang DY.

Cancer Chemother Pharmacol. 2010 Oct;66(5):889-97. doi: 10.1007/s00280-009-1235-y. Epub 2010 Jan 21.

PMID:
20091311
11.

Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.

Kubota K, Kawahara M, Ogawara M, Nishiwaki Y, Komuta K, Minato K, Fujita Y, Teramukai S, Fukushima M, Furuse K; Japan Multi-National Trial Organisation.

Lancet Oncol. 2008 Dec;9(12):1135-42. doi: 10.1016/S1470-2045(08)70261-4. Epub 2008 Nov 13.

PMID:
19013107
12.

Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.

Kosmas C, Tsavaris N, Vadiaka M, Stavroyianni N, Koutras A, Malamos N, Onyenadum A, Rokana S, Polyzos A, Kalofonos HP.

Cancer. 2001 Dec 1;92(11):2902-10.

PMID:
11753965
13.

Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001).

Grossi F, Belvedere O, Fasola G, Barbone F, Rizzato S, Sibau A, Recchia L, Vigevani E, Ceschia T, Morelli A, Guglielmi A, Puglisi F, Follador A, Talmassons G, Sobrero AF.

Lung Cancer. 2004 Oct;46(1):99-106.

PMID:
15364137
14.

An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.

Pectasides D, Kalofonos HP, Samantas E, Nicolaides C, Papacostas P, Onyenadum A, Visvikis A, Skarlos D, Fountzilas G.

Anticancer Res. 2001 Jul-Aug;21(4B):3005-10.

PMID:
11712802
15.

Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.

Gebbia V, Galetta D, Caruso M, Verderame F, Pezzella G, Valdesi M, Borsellino N, Pandolfo G, Durini E, Rinaldi M, Loizzi M, Gebbia N, Valenza R, Tirrito ML, Varvara F, Colucci G; Gruppo Ocologico Italia Meridionale.

Lung Cancer. 2003 Feb;39(2):179-89.

PMID:
12581571
16.

Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.

Kakolyris S, Papadakis E, Tsiafaki X, Kalofonos C, Rapti A, Toubis M, Bania E, Kouroussis C, Chainis K, Androulakis N, Agelaki S, Sarra E, Vardakis N, Georgoulias V; Greek Cooperative Group for Lung Cancer.

Lung Cancer. 2001 May;32(2):179-87.

PMID:
11325489
17.

Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer. A single institution phase II study.

Dongiovanni D, Fissore C, Berruti A, Buffoni L, Addeo A, Barone C, Polimeni MA, Ottaviani D, Bertetto O, Dongiovanni V.

Lung Cancer. 2005 Feb;47(2):269-75.

PMID:
15639726
18.

Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.

Douillard JY, Gervais R, Dabouis G, Le Groumellec A, D'Arlhac M, Spaeth D, Coudert B, Caillaud D, Monnier A, Clary C, Maury B, Mornet M, Rivière A, Clouet P, Couteau C.

Ann Oncol. 2005 Jan;16(1):81-9.

PMID:
15598943
19.

Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.

Kosmas C, Tsavaris N, Panopoulos C, Vadiaka M, Stavroyianni N, Kourelis T, Malamos N, Antonopoulos M, Kalofonos HP.

Eur J Cancer. 2001 May;37(8):972-8.

PMID:
11334721
20.

Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).

Hosoe S, Komuta K, Shibata K, Harada H, Iwamoto Y, Ohsaki Y, Morioka T, Origasa H, Fukushima M, Furuse K, Kawahara M.

Br J Cancer. 2003 Feb 10;88(3):342-7.

Supplemental Content

Support Center